Navigation Links
FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Date:9/27/2007

CLARITY and COMMIT trials."

The 300mg tablet is bioequivalent to four 75mg FDA approved tablets of PLAVIX. The 300mg tablet of clopidogrel will be available in the U.S. later this year and is also currently under European Medicines Evaluation Agency (EMEA) review.

About PLAVIX

PLAVIX is a prescription antiplatelet medicine taken once a day that helps keep platelets in the blood from sticking together and forming clots. Since its initial approval on November 17, 1997, by the U.S. Food and Drug Administration, PLAVIX has been prescribed to more than 52 million patients worldwide. The new 300mg loading dose tablet reinforces the strong commitment of two research and development pharmaceutical companies dedicated to improving patient health.

The efficacy and safety of PLAVIX have been established through four landmark clinical trials involving more than 81,000 patients. Plavix is the only widely available prescription antiplatelet that provides proven protection against a future heart attack or stroke for patients with ACS (UA, NSTEMI, STEMI) and recent MI, recent Stroke, or established peripheral artery disease.

PLAVIX has demonstrated early and long-term risk reduction for patients at risk for atherothrombotic events in important clinical trials. In the CURE trial, patients with unstable angina (UA) and non-ST segment elevation myocardial infarction (NSTEMI) receiving PLAVIX with aspirin were followed for up to one year, and in the CAPRIE trial, patients with recent MI, recent ischemic stroke, or established peripheral artery disease receiving PLAVIX alone were followed for up to three years.

PLAVIX is marketed worldwide by sanofi-aventis (Paris Bourse: EURONEXT: SAN; New York: NYSE: SNY) and Bristol-Myers Squibb Company (NYSE:

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. Integration of the LEADseeker Multimodality Imaging System with automated plate loading and incubation using Overlord Instrument software
9. Marquette targets illegal downloading
10. Though VC investing is down, reloading on new funds is rising
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 22, 2013 First patients dosed ... glycopyrronium bromide designed using Prosonix, particle engineering platform ... portfolio of inhaled Respiratory Medicines by Design , ... that will assess its effect on lung function and ... with moderate to severe chronic obstructive pulmonary disease (COPD). ...
(Date:5/21/2013)... new study led by George Washington University Professor ... of ice in small droplets is strongly size-dependent, ... the nanoscale. The formation of ice at the ... whose answer also has important implications for climate ... of ice from supercooled water is generally initiated ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Smarter Security, ... security solutions, today announced that Genzyme, a Sanofi company ... of Door Detective® CL for a multi-use facility in ... in four other Genzyme buildings, this latest order underscores ... the tailgate detection device improving doorway access ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... by Improving ... Information Management, MILFORD, ... announced that it has joined the BioIT Alliance, an,initiative spearheaded ... and software companies,working together to realize the potential of personalized ...
... StopAfib.org, at, http://www.StopAfib.org, announces that September is Atrial ... called afib or AF., Once considered benign, this ... or stroke. Every five minutes, someone in the,U.S. has ... killer and the #1 cause of,permanent disability, and takes ...
... $15 million development milestone payment to InterMune - ... - Roche to lead ITMN-191 program in Phase 2 -, ... ) today announced that InterMune has earned a $15 million,development ... virus (HCV) NS3 protease inhibitor compound ITMN-191,(referred to as R7227 ...
Cached Biology Technology:Waters Brings Advanced Laboratory Data Management to Microsoft's BioIT Alliance 2Waters Brings Advanced Laboratory Data Management to Microsoft's BioIT Alliance 3Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4
(Date:5/22/2013)... engineers must join together in a major new effort ... crisis in providing Earth,s people with clean water that ... of a comment article in the current edition of ... of the American Chemical Society (ACS), the world,s largest ... Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain that ...
(Date:5/22/2013)... can endanger the whole organism, as they may lead ... in Munich now report how byproducts of respiration cause ... DNA in our cells controls the form and function ... for this are encoded in the linear sequence of ... (A), cytosine (C), guanine (G) and thymine (T). Random ...
(Date:5/22/2013)... pollinating insects and wild plants have slowed in recent ... by the University of Leeds and the Naturalis Biodiversity ... reductions in the diversity of species in Britain, Belgium ... But the picture brightened markedly after 1990, with a ... hoverflies and wild plants. , Professor Bill ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... CORVALLIS, Ore. A 700-mile security wall under construction ... alter the movement and "connectivity" of wildlife, biologists say, ... populations of some species. However, technology and alterations ... animals to move more freely between the two countries, ...
... survival is now better understood. For the first time, ... National Laboratory observed the chemical changes in individual cells ... them. The team tracked the chemical changes in ... can only exist in an oxygen-free environment. They exposed ...
... has discovered a key process in cell growth that can ... assistant professor of biochemistry, found that an overabundance of the ... well as a shortage of the p53 molecule, will lead ... Plk1 molecule indirectly attacks p53 in a process called ubiquitination. ...
Cached Biology News:US-Mexico border wall could threaten wildlife species 2US-Mexico border wall could threaten wildlife species 3US-Mexico border wall could threaten wildlife species 4Scientists track chemical changes in cells as they endure extreme conditions 2Scientists track chemical changes in cells as they endure extreme conditions 3Protein can help cells or cause cancer, Purdue researcher finds 2
Request Info...
...
...
... Inhibits several important steps of angiogenesis including proliferation, ... Also reduces intracellular reactive oxygen species (ROS) level, ... cells. Formula: ... MolWeight: 360.31484 ...
Biology Products: